SMMT SEC filings (2026)
CIK 1599298 · Pharmaceutical Preparations (SIC 2834) · fiscal year ends in December
554 filings on EDGAR since 2014 · 13 annual, 18 quarterly, 242 current · financial statements · earnings
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by what they covered, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
September 2026
- Sep 298-K8-K · Material definitive agreement; Unregistered sale of equity; Charter, bylaws or fiscal-year change; Other events
- Sep 158-K8-K · Other events
- Sep 148-K8-K · Other events
- Sep 38-K8-K · Other events
August 2026
- Aug 268-K8-K · Other events
- Aug 58-K8-K · Other events
July 2026
- Jul 23EarningsEarnings release — EPS −$0.28 vs −$0.26 est. (−7.7%) 8.8%
- Jul 23ReportQuarterly report, Q2 2026 — net income −$215.7M, EPS −$0.28
- Jul 238-K8-K · Material definitive agreement
- Jul 228-K8-K · Other events
June 2026
- Jun 12Insider buyDUGGAN ROBERT W (Co-Chief Executive Officer · Director · 10% owner) bought 3,810,000 shares for $50.0M at $13.12
- Jun 12Insider buyZanganeh Mahkam (Co-Chief Executive Officer · Director · 10% owner) bought 3,810,000 shares for $50.0M at $13.12
- Jun 128-K8-K · Shareholder vote results
- Jun 118-K8-K · Regulation FD disclosure
- Jun 4Insider buyDUGGAN ROBERT W (Co-Chief Executive Officer · Director · 10% owner) bought 100,000 shares for $1.5M at $14.60
- Jun 4Insider buyZanganeh Mahkam (Co-Chief Executive Officer · Director · 10% owner) bought 100,000 shares for $1.5M at $14.60
- Jun 4Insider buySoni Manmeet Singh (COO and CFO · Director) bought 50,000 shares for $722K at $14.43–$14.46
- Jun 38-K8-K · Other events
- Jun 18-K8-K · Other events
April 2026
- Apr 30EarningsEarnings release — EPS −$0.24 vs −$0.33 est. (+27.3%) 24.9%
- Apr 30ReportQuarterly report, Q1 2026 — net income −$189.4M, EPS −$0.24
- Apr 17ProxyProxy · Additional proxy materials
- Apr 17ProxyProxy · Annual report to shareholders
- Apr 17ProxyProxy · Proxy statement
- Apr 6ProxyProxy · Preliminary proxy statement
February 2026
- Feb 23EarningsEarnings release — EPS −$0.29 vs −$0.22 est. (−31.8%) 0.2%
- Feb 23ReportAnnual report, FY2025 — net income −$1.08B, EPS −$1.44
January 2026
- Jan 298-K8-K · Other events
- Jan 128-K8-K · Results of operations; Regulation FD disclosure
November 2025
- Nov 78-K8-K · Other events
October 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold nothing and bought $103.6M in 5 purchases; 9 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Jun 12, 2026Form 4 | DUGGAN ROBERT WCo-Chief Executive Officer · Director · 10% ownerBought · $50.0M · 3,810,000 sh |
| Jun 12, 2026Form 4 | Zanganeh MahkamCo-Chief Executive Officer · Director · 10% ownerBought · $50.0M · 3,810,000 sh |
| Jun 4, 2026Form 4 | DUGGAN ROBERT WCo-Chief Executive Officer · Director · 10% ownerBought · $1.5M · 100,000 sh |
| Jun 4, 2026Form 4 | Zanganeh MahkamCo-Chief Executive Officer · Director · 10% ownerBought · $1.5M · 100,000 sh |
| Jun 4, 2026Form 4 | Soni Manmeet SinghCOO and CFO · DirectorBought · $722K · 50,000 sh |
Awards, exercises, withholding and plan purchases · 9 transactions
| Date | Insider |
|---|---|
| Jan 8, 2026Form 4 | Anand BhaskarChief Accounting OfficerAward · Stock Option (right to buy) · — · 30,000 sh |
| Jan 2, 2026Form 4 | Clark Kenneth ADirectorAward · Stock Option (right to buy) · $156K+ · 52,796 sh |
| Jan 2, 2026Form 4 | DUGGAN ROBERT WCo-Chief Executive Officer · Director · 10% ownerAward · Stock Option (right to buy) · $98K · 11,232 sh |
| Jan 2, 2026Form 4 | Zanganeh MahkamCo-Chief Executive Officer · Director · 10% ownerAward · Stock Option (right to buy) · $98K · 11,232 sh |
| Jan 2, 2026Form 4 | Huber JeffDirectorAward · Stock Option (right to buy) · $87K+ · 44,885 sh |
| Jan 2, 2026Form 4 | Booth Robert F.DirectorAward · Stock Option (right to buy) · $63K+ · 42,180 sh |
| Jan 2, 2026Form 4 | Cesano AlessandraDirectorAward · Stock Option (right to buy) · $28K+ · 38,219 sh |
| Jan 2, 2026Form 4 | Ronaghi MostafaDirectorAward · Stock Option (right to buy) · — · 35,000 sh |
| Jan 2, 2026Form 4 | Xia YuDirectorAward · Stock Option (right to buy) · — · 35,000 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K is described by its items. A form opens the document on EDGAR, or the filing’s index where it furnishes exhibits (an earnings release is the 8-K’s Exhibit 99.1).
2026 · 24 filings
| Filed | What it is |
|---|---|
| Sep 29, 20268-K | Material definitive agreement; Unregistered sale of equity; Charter, bylaws or fiscal-year change; Other events |
| Sep 15, 20268-K | Other events |
| Sep 14, 20268-K | Other events |
| Sep 3, 20268-K | Other events |
| Aug 26, 20268-K | Other events |
| Aug 5, 20268-K | Other events |
| Jul 23, 20268-K | Material definitive agreement |
| Jul 23, 202610-Q | Quarterly report, Q2 2026 — net income −$215.7M, EPS −$0.28 |
| Jul 23, 20268-K | Earnings release — EPS −$0.28 vs −$0.26 est. (−7.7%) 8.8% |
| Jul 22, 20268-K | Other events |
| Jun 12, 20268-K | Shareholder vote results |
| Jun 11, 20268-K | Regulation FD disclosure |
| Jun 3, 20268-K | Other events |
| Jun 1, 20268-K | Other events |
| Apr 30, 202610-Q | Quarterly report, Q1 2026 — net income −$189.4M, EPS −$0.24 |
| Apr 30, 20268-K | Earnings release — EPS −$0.24 vs −$0.33 est. (+27.3%) 24.9% |
| Apr 17, 2026DEFA14A | Additional proxy materials |
| Apr 17, 2026ARS | Annual report to shareholders |
| Apr 17, 2026DEF 14A | Proxy statement |
| Apr 6, 2026PRE 14A | Preliminary proxy statement |
| Feb 23, 202610-K | Annual report, FY2025 — net income −$1.08B, EPS −$1.44 |
| Feb 23, 20268-K | Earnings release — EPS −$0.29 vs −$0.22 est. (−31.8%) 0.2% |
| Jan 29, 20268-K | Other events |
| Jan 12, 20268-K | Results of operations; Regulation FD disclosure |
2025 · 21 filings
| Filed | What it is |
|---|---|
| Nov 7, 20258-K | Other events |
| Oct 22, 20258-K | Material definitive agreement; Unregistered sale of equity; Regulation FD disclosure |
| Oct 20, 202510-Q | Quarterly report, Q3 2025 — net income −$231.8M, EPS −$0.31 |
| Oct 20, 20258-K | Earnings release — EPS −$0.31 vs −$0.14 est. (−121.4%) 4.5% |
| Sep 8, 20258-K | Other events |
| Aug 11, 20258-K | Results of operations |
| Aug 11, 20258-K | Material definitive agreement |
| Aug 11, 202510-Q | Quarterly report, Q2 2025 — net income −$565.7M, EPS −$0.76 |
| Jun 20, 20258-K | Material definitive agreement |
| Jun 17, 20258-K | Shareholder vote results |
| May 30, 20258-K | Other events |
| May 1, 202510-Q | Quarterly report, Q1 2025 — net income −$62.9M, EPS −$0.09 |
| May 1, 20258-K | Results of operations; Regulation FD disclosure |
| Apr 29, 2025ARS | Annual report to shareholders |
| Apr 29, 2025DEF 14A | Proxy statement |
| Apr 25, 20258-K | Other events |
| Apr 23, 20258-K | Other events |
| Feb 24, 202510-K | Annual report, FY2024 — revenue $0, net income −$221.3M, EPS −$0.31 |
| Feb 24, 20258-K | Results of operations; Regulation FD disclosure |
| Jan 24, 20258-K | Directors or officers; compensation; Other events |
| Jan 13, 20258-K | Results of operations; Regulation FD disclosure |
2024 · 28 filings
| Filed | What it is |
|---|---|
| Oct 30, 202410-Q | Quarterly report, Q3 2024 — revenue $0, net income −$56.3M, EPS −$0.08 |
| Oct 30, 20248-K | Results of operations; Regulation FD disclosure |
| Sep 12, 20248-K | Material definitive agreement; Unregistered sale of equity; Regulation FD disclosure |
| Sep 9, 20248-K | Regulation FD disclosure; Other events |
| Aug 6, 202410-Q | Quarterly report, Q2 2024 — net income −$60.4M, EPS −$0.09 |
| Aug 6, 20248-K | Results of operations; Regulation FD disclosure |
| Jun 27, 20248-K | Material definitive agreement; Directors or officers; compensation |
| Jun 17, 20248-K | Directors or officers; compensation; Shareholder vote results |
| Jun 13, 2024DEFA14A | Additional proxy materials |
| Jun 3, 20248-K | Material definitive agreement; Unregistered sale of equity; Regulation FD disclosure |
| Jun 3, 20248-K | Regulation FD disclosure; Other events |
| May 30, 20248-K | Other events |
| May 24, 20248-K | Other events |
| May 13, 20248-K | Material definitive agreement |
| May 1, 20248-K | Results of operations |
| May 1, 202410-Q | Quarterly report, Q1 2024 — net income −$43.5M, EPS −$0.06 |
| Apr 25, 2024DEF 14A | Proxy statement |
| Apr 11, 20248-K | Directors or officers; compensation |
| Apr 3, 20248-K | Directors or officers; compensation |
| Mar 22, 20248-K | Other events |
| Mar 12, 20248-K | Regulation FD disclosure |
| Mar 5, 20248-K | Other events |
| Feb 20, 20248-K | Results of operations |
| Feb 20, 202410-K | Annual report, FY2023 — revenue $0 (−100% y/y), net income −$614.9M, EPS −$0.99 |
| Feb 15, 20248-K | Regulation FD disclosure |
| Feb 8, 20248-K | Other events |
| Jan 8, 20248-K | Results of operations; Regulation FD disclosure |
| Jan 3, 20248-K | Other events |
2023 · 26 filings — 19 × 8-K, 3 × 10-Q, 2 × DEF 14A and 2 other forms
| Filed | What it is |
|---|---|
| Nov 7, 202310-Q | Quarterly report, Q3 2023 — revenue $0 (−100% y/y), net income −$21.3M, EPS −$0.03 |
| Sep 19, 2023DEF 14A | Proxy statement |
| Sep 8, 2023PRE 14A | Preliminary proxy statement |
| Aug 9, 202310-Q | Quarterly report, Q2 2023 — revenue $0 (−100% y/y), net income −$14.7M, EPS −$0.02 |
| May 11, 202310-Q | Quarterly report, Q1 2023 — revenue $0 (−100% y/y), net income −$542.4M, EPS −$1.43 |
| Apr 21, 2023DEF 14A | Proxy statement |
| Mar 9, 202310-K | Annual report, FY2022 — revenue $705K (−61% y/y), net income −$78.8M, EPS −$0.41 |
19 current reports (8-K) not listed; the year is on EDGAR.
2022 · 36 filings — 25 × 8-K, 3 × 10-Q, 3 × DEF 14A and 4 other forms
| Filed | What it is |
|---|---|
| Dec 21, 202210-K/A | Annual report, amended |
| Dec 13, 2022DEF 14A | Proxy statement |
| Nov 29, 2022PRE 14A | Preliminary proxy statement |
| Nov 9, 202210-Q | Quarterly report, Q3 2022 — revenue $220K (−83% y/y), net income −$21.4M, EPS −$0.10 |
| Aug 11, 202210-Q | Quarterly report, Q2 2022 — revenue $235K (+312% y/y), net income −$16.8M, EPS −$0.12 |
| Jul 6, 2022DEF 14A | Proxy statement |
| Jun 24, 2022PRE 14A | Preliminary proxy statement |
| Jun 3, 2022DEFA14A | Additional proxy materials |
| May 11, 202210-Q | Quarterly report, Q1 2022 — revenue $250K (+30% y/y), net income −$21.4M, EPS −$0.15 |
| Apr 29, 2022DEF 14A | Proxy statement |
| Mar 17, 202210-K | Annual report |
25 current reports (8-K) not listed; the year is on EDGAR.
2021 · 26 filings — 20 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 15, 202110-Q | Quarterly report, Q3 2021 — revenue $1.3M (+623% y/y), net income −$19.6M, EPS −$0.20 |
| Aug 12, 202110-Q | Quarterly report, Q2 2021 — revenue $57K (−66% y/y), net income −$24.4M, EPS −$0.27 |
| Jun 2, 2021DEFA14A | Additional proxy materials |
| May 17, 202110-Q | Quarterly report, Q1 2021 — revenue $192K (−41% y/y), net income −$17.5M, EPS −$0.21 |
| Apr 29, 2021DEF 14A | Proxy statement |
| Mar 31, 202110-K | Annual report, FY2020 — revenue $860K (+16% y/y), net income −$52.7M, EPS −$0.76 |
20 current reports (8-K) not listed; the year is on EDGAR.
2020 · 30 filings — 20 × 6-K, 7 × 8-K, 1 × 10-Q and 2 other forms
2019 · 18 filings — 16 × 6-K, 1 × 20-F, 1 × 6-K/A
2018 · 22 filings — 21 × 6-K, 1 × 20-F
2017 · 20 filings — 19 × 6-K, 1 × 20-F
2016 · 19 filings — 18 × 6-K, 1 × 20-F
Counted, not listed; the year is on EDGAR.
2015 · 22 filings — 21 × 6-K, 1 × 20-F
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 18 filings — 14 × 4, 2 × 424B5, 1 × S-3ASR and 1 other form
| Filed | What it is |
|---|---|
| Jul 23, 2026424B5 | Prospectus supplement |
| Jun 12, 20264 | Insider transaction (Form 4) |
| Jun 12, 20264 | Insider transaction (Form 4) |
| Jun 10, 2026424B5 | Prospectus supplement |
| Jun 9, 2026S-3ASR | Automatic shelf registration |
| Jun 4, 20264 | Insider transaction (Form 4) |
| Jun 4, 20264 | Insider transaction (Form 4) |
| Jun 4, 20264 | Insider transaction (Form 4) |
| Feb 23, 2026S-8 | Employee stock plan registration |
| Jan 12, 20264 | Insider transaction (Form 4) |
| Jan 6, 20264 | Insider transaction (Form 4) |
| Jan 6, 20264 | Insider transaction (Form 4) |
| Jan 6, 20264 | Insider transaction (Form 4) |
| Jan 6, 20264 | Insider transaction (Form 4) |
| Jan 6, 20264 | Insider transaction (Form 4) |
| Jan 6, 20264 | Insider transaction (Form 4) |
| Jan 6, 20264 | Insider transaction (Form 4) |
| Jan 6, 20264 | Insider transaction (Form 4) |
2025 · 30 filings — 25 × 4, 1 × 424B5, 1 × CORRESP and 3 other forms
| Filed | What it is |
|---|---|
| Oct 29, 2025S-3ASR | Automatic shelf registration |
| Oct 23, 20254 | Insider transaction (Form 4) |
| Oct 23, 20254 | Insider transaction (Form 4) |
| Oct 23, 20254 | Insider transaction (Form 4) |
| Oct 23, 20254 | Insider transaction (Form 4) |
| Oct 23, 20254 | Insider transaction (Form 4) |
| Sep 19, 20254 | Insider transaction (Form 4) |
| Sep 11, 20254 | Insider transaction (Form 4) |
| Sep 11, 20254 | Insider transaction (Form 4) |
| Aug 11, 2025424B5 | Prospectus supplement |
| Jun 2, 20254 | Insider transaction (Form 4) |
| Jun 2, 20254 | Insider transaction (Form 4) |
| May 19, 2025S-8 | Employee stock plan registration |
| May 1, 20254 | Insider transaction (Form 4) |
| May 1, 20254 | Insider transaction (Form 4) |
| May 1, 20254 | Insider transaction (Form 4) |
| May 1, 20254 | Insider transaction (Form 4) |
| Apr 9, 20254 | Insider transaction (Form 4) |
| Apr 9, 20254 | Insider transaction (Form 4) |
| Jan 21, 2025UPLOAD | Letter from the SEC staff |
| Jan 14, 20254 | Insider transaction (Form 4) |
| Jan 6, 20254 | Insider transaction (Form 4) |
| Jan 6, 20254 | Insider transaction (Form 4) |
| Jan 6, 20254 | Insider transaction (Form 4) |
| Jan 6, 20254 | Insider transaction (Form 4) |
The newest 25 of 30 shown; the full year is on EDGAR.
2024 · 37 filings — 21 × 4, 3 × 3, 2 × D and 9 other forms
| Filed | What it is |
|---|---|
| Dec 19, 2024UPLOAD | Letter from the SEC staff |
| Oct 15, 20244 | Insider transaction (Form 4) |
| Oct 3, 20244 | Insider transaction (Form 4) |
| Sep 26, 2024D | Other filings |
| Sep 19, 2024S-3ASR | Automatic shelf registration |
| Sep 13, 20244 | Insider transaction (Form 4) |
| Sep 13, 20244 | Insider transaction (Form 4) |
| Sep 13, 2024SC 13D/A | Active holder above 5% (Schedule 13D), amended |
| Sep 13, 20244 | Insider transaction (Form 4) |
| Sep 13, 20244 | Insider transaction (Form 4) |
| Sep 13, 20244 | Insider transaction (Form 4) |
| Aug 23, 20244 | Insider transaction (Form 4) |
| Aug 23, 20244 | Insider transaction (Form 4) |
| Aug 6, 2024S-3ASR | Automatic shelf registration |
| Jun 27, 20244 | Insider transaction (Form 4) |
| Jun 27, 20243 | Initial insider holdings (Form 3) |
| Jun 18, 2024D | Other filings |
| May 13, 2024424B5 | Prospectus supplement |
| May 1, 2024S-8 | Employee stock plan registration |
| Apr 15, 20244 | Insider transaction (Form 4) |
| Apr 15, 20243 | Initial insider holdings (Form 3) |
| Apr 4, 20244 | Insider transaction (Form 4) |
| Apr 4, 20244 | Insider transaction (Form 4) |
| Apr 4, 20243 | Initial insider holdings (Form 3) |
| Mar 27, 20244 | Insider transaction (Form 4) |
The newest 25 of 37 shown; the full year is on EDGAR.
2023 · 28 filings — 12 × 4, 3 × CORRESP, 2 × 4/A and 8 other forms
Counted, not listed; the year is on EDGAR.
2022 · 25 filings — 14 × 4, 3 × 3, 2 × CT ORDER and 5 other forms
Counted, not listed; the year is on EDGAR.
2021 · 27 filings — 12 × 4, 4 × 3, 3 × SC 13D/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2020 · 39 filings — 10 × 3, 8 × SC 13D/A, 7 × 4 and 10 other forms
Counted, not listed; the year is on EDGAR.
2019 · 12 filings — 3 × SC 13D/A, 1 × 424B3, 1 × CORRESP and 7 other forms
Counted, not listed; the year is on EDGAR.
2018 · 10 filings — 4 × CT ORDER, 1 × CORRESP, 1 × EFFECT and 4 other forms
Counted, not listed; the year is on EDGAR.
2017 · 6 filings — 2 × 424B5, 2 × CT ORDER, 1 × SC 13D/A and 1 other form
Counted, not listed; the year is on EDGAR.
2016 · 8 filings — 2 × CT ORDER, 1 × CORRESP, 1 × EFFECT and 4 other forms
Counted, not listed; the year is on EDGAR.
2015 · 19 filings — 3 × UPLOAD, 2 × CORRESP, 2 × EFFECT and 11 other forms
Counted, not listed; the year is on EDGAR.
2014 · 3 filings — 1 × D, 1 × DRS, 1 × UPLOAD
Counted, not listed; the year is on EDGAR.
About this data
Summit Therapeutics Inc. Common Stock (SMMT) has 554 filings on EDGAR going back to 2014: 13 annual reports, 18 quarterly reports and 242 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 23, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Sep 29, 2026, covered material definitive agreement; unregistered sale of equity; charter, bylaws or fiscal-year change; other events. Over the last 13 months insiders sold nothing and bought $103.6M in 5 purchases; 9 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Summit Therapeutics Inc. Common Stock, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read SMMT's latest 10-K?
- SMMT's latest annual report, a 10-K, was filed on Feb 23, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did SMMT last file an 8-K?
- On Sep 29, 2026: material definitive agreement; unregistered sale of equity; charter, bylaws or fiscal-year change; other events. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 23, 2026.
- Are SMMT insiders buying or selling?
- Over the last 13 months insiders sold nothing and bought $103.6M in 5 purchases; 9 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has SMMT made?
- 554 filings are on EDGAR under the registrant records that have been Summit Therapeutics Inc. Common Stock, going back to 2014; 129 of them are insider ownership forms (Forms 3, 4, 5 and 144).